Mankind Pharma
Mankind Pharma Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Mankind Pharma expects progressive recovery and double-digit growth in domestic sales, with specific focus on both Chronic and Acute segments. Mankind Pharma expects double-digit growth for the full year FY27, driven by sequential recovery in both Chronic and Acute segments.
From Mankind Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Mankind Pharma expects progressive recovery and double-digit growth in domestic sales, with specific focus on both Chronic and Acute segments.
- Chronic portfolio is growing strongly (15.8% growth reported), with a medium-term target to increase its share from 40% to 50%.
- Acute segment has shown steady recovery, reaching growth comparable to Indian Pharmaceutical Market (IPM) at 10.9%.
- BSV (specialty business) is expected to grow in the high teens with balanced domestic and international expansion.
- New divisions such as Vistar aim to scale lesser-focused brands, adding to future growth.
- International business is also growing strongly (29% YoY growth reported).
- Volume growth has improved to 4.7% from 2.3% last fiscal year.
- Management targets to outperform IPM consistently over the next 9 months and medium term.
- Innovation and R&D investments with AI-led drug discovery programs are expected to support sustainable growth.
Profitability & Margins
See what Mankind Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex spend in Q1 FY27 was INR 198 crores, higher than INR 127 crores in Q1 FY26.
- Capex as a percentage of revenue is 4.9%, below the guidance of 6% to 7% for FY27.
- Company has enhanced the R&D biotech facility, indicating investment in biotech capabilities.
- Addition of a biotech facility as part of strategic changes.
- Focus on innovation and execution as strategic priorities.
- No specific mention of new large-scale capital or strategic investments beyond existing biotech enhancements.
- Overall, maintaining prudent financial strategy with focus on sustainable growth and capacity expansion.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Mankind Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Mankind Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.4K Cr, net profit ₹559 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mankind Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Mankind Pharma Q1 FY27 results?
Mankind Pharma expects progressive recovery and double-digit growth in domestic sales, with specific focus on both Chronic and Acute segments. Mankind Pharma expects double-digit growth for the full year FY27, driven by sequential recovery in both Chronic and Acute segments.
What is Mankind Pharma share price analysis?
Mankind Pharma currently shows a below-average growth signal. The stock trades at a P/E of 46.2 with a market cap of ₹98,458 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma planning capital expenditure?
Capex spend in Q1 FY27 was INR 198 crores, higher than INR 127 crores in Q1 FY26.
Keep Mankind Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.